Pomegra
Dutch biotech RougeTx launched with a $58M Series A backed by BioGeneration, Angelini, Aurea and Kurma to take oral HHT drug RTX-001 into the clinic.
Key Takeaways
- RougeTx closed a $58M (about €52M) Series A on October 6, 2026; valuation was not disclosed.
- Lead drug RTX-001 is a once-daily oral candidate for hereditary hemorrhagic telangiectasia.
- The Leiden University Medical Center spin-out has not yet dosed a patient.
Lead
RougeTx, a Leiden University Medical Center spin-out based in Naarden, the Netherlands, launched on October 6, 2026 with a $58 million Series A. The money will move RTX-001, a potential once-daily oral treatment for hereditary hemorrhagic telangiectasia (HHT), toward first-in-human testing. The company also plans a Phase IIa study in HHT patients, designed as double-blinded and placebo-controlled.
Who Funded the Round?
BioGeneration Ventures, the founding investor, and Angelini Ventures co-led the round. Kurma Partners and Aurea, the co-investment facility of the European Investment Bank, also took major positions. Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures participated.
The company did not disclose a valuation or the split between investors. Because RougeTx is announcing itself and its Series A together, there is no earlier priced round to compare against. The cap table is the only signal: a founding investor that stayed in as co-lead, plus a strategic pharma-backed fund and a public development bank.
Five investors take board seats: Edward van Wezel of BioGeneration, Regina Hodits of Angelini Ventures, Hadrien Bouchez of Kurma, Elizabeth Roper of Epidarex and Stéphane Verdood of Vesalius. Andrew Lightfoot is chief executive and Sandra Glucksmann is executive chair. Co-founder Franck Lebrin stays on as scientific advisor.
What Does RTX-001 Do?
RTX-001 is a small molecule meant to restore the attachment of pericytes to blood vessels. Pericytes are cells that wrap around vessels, and the company's premise is that stabilizing them can stop fragile vessels from bleeding. The molecular target has not been disclosed.
The science traces to more than 20 years of vascular biology work originally done at Inserm. Lebrin authored a 2010 Nature Medicine study showing that thalidomide reduced nosebleeds in HHT patients. RougeTx has also built a discovery platform called periSCOPE. It is meant to produce further candidates for other diseases driven by pericyte dysfunction.
Why Is HHT a Difficult Target?
HHT is the second most common inherited bleeding disorder, and it has no approved therapy. It causes abnormal arteriovenous malformations that produce recurrent nose and gastrointestinal bleeding, iron deficiency and chronic anemia. Complications can reach the lungs, liver and brain.
Patients today rely on off-label drugs. These include pomalidomide, systemic bevacizumab and the oral kinase inhibitor pazopanib, along with procedures to control bleeding. RTX-001 would compete with those options on convenience and on the premise that it acts on vessel stability rather than on angiogenesis signaling.
What Are the Risks?
The risk is clinical. RougeTx is a preclinical company, and a mechanism that works in laboratory models can still fail in people. HHT trials usually depend on bleeding-based endpoints, such as nosebleed frequency and hemoglobin, which can be noisy in small patient populations. A placebo-controlled Phase IIa study of adequate size is expensive, and $58 million has to cover it alongside the first-in-human work and platform expansion.
The company has not said when it expects to dose its first patient. That leaves the pace of progress unclear, and the Series A may need to be followed by a larger round before pivotal data arrive.
What Does This Say About European Biotech Funding?
The syndicate is mostly European specialist funds, with one pharma-affiliated investor and the EIB. Public co-investment through Aurea is now a common feature of European life-science rounds of this size. A $58 million Series A for a preclinical asset points to investors willing to pay for rare-disease programs with a defined patient population and a known biological hook. It does not, on its own, say anything about exit prospects.
Outlook
RougeTx enters with fresh capital, an experienced board and a mechanism that differs from the repurposed drugs used in HHT today. The next milestones are first-in-human data for RTX-001 and the start of the Phase IIa study, neither of which has a disclosed date. Until a patient is dosed and bleeding endpoints are measured, the value of the round rests on the strength of the science and the investor group behind it.
